JP2008517940A5 - - Google Patents

Download PDF

Info

Publication number
JP2008517940A5
JP2008517940A5 JP2007538147A JP2007538147A JP2008517940A5 JP 2008517940 A5 JP2008517940 A5 JP 2008517940A5 JP 2007538147 A JP2007538147 A JP 2007538147A JP 2007538147 A JP2007538147 A JP 2007538147A JP 2008517940 A5 JP2008517940 A5 JP 2008517940A5
Authority
JP
Japan
Prior art keywords
composition
seq
irna
sense strand
respiratory virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007538147A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008517940A (ja
JP5037349B2 (ja
Filing date
Publication date
Priority claimed from US11/151,893 external-priority patent/US7592322B2/en
Application filed filed Critical
Publication of JP2008517940A publication Critical patent/JP2008517940A/ja
Publication of JP2008517940A5 publication Critical patent/JP2008517940A5/ja
Application granted granted Critical
Publication of JP5037349B2 publication Critical patent/JP5037349B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007538147A 2004-10-22 2005-10-21 ＲＳＶ、ＰＩＶおよび他の呼吸器系ウイルスのＲＮＡｉ調節とその使用法 Expired - Fee Related JP5037349B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US62155204P 2004-10-22 2004-10-22
US60/621,552 2004-10-22
US11/151,893 US7592322B2 (en) 2004-10-22 2005-06-14 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US11/151,893 2005-06-14
US11/151,976 2005-06-14
US11/151,976 US20060089324A1 (en) 2004-10-22 2005-06-14 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
PCT/US2005/038269 WO2006062596A2 (en) 2004-10-22 2005-10-21 RNAi MODULATION OF RSV, PIV AND OTHER RESPIRATORY VIRUSES AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2008517940A JP2008517940A (ja) 2008-05-29
JP2008517940A5 true JP2008517940A5 (enExample) 2008-11-27
JP5037349B2 JP5037349B2 (ja) 2012-09-26

Family

ID=36578352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007538147A Expired - Fee Related JP5037349B2 (ja) 2004-10-22 2005-10-21 ＲＳＶ、ＰＩＶおよび他の呼吸器系ウイルスのＲＮＡｉ調節とその使用法

Country Status (12)

Country Link
US (2) US7592322B2 (enExample)
EP (1) EP1806968B1 (enExample)
JP (1) JP5037349B2 (enExample)
KR (1) KR101193825B1 (enExample)
CN (1) CN101087527B (enExample)
AU (1) AU2005314617B2 (enExample)
BR (1) BRPI0517286A (enExample)
CA (1) CA2584309A1 (enExample)
MX (1) MX2007004692A (enExample)
NO (1) NO20071953L (enExample)
RU (1) RU2494745C2 (enExample)
WO (1) WO2006062596A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP2221377B2 (en) 2002-02-01 2017-05-17 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US8258288B2 (en) * 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US7297786B2 (en) * 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
US7790878B2 (en) * 2004-10-22 2010-09-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
JP5081630B2 (ja) 2005-01-07 2012-11-28 アルナイラム ファーマシューティカルズ， インコーポレイテッド ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法
DK2308514T3 (da) 2007-03-23 2013-09-02 To Bbb Holding B V Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren
US20100215588A1 (en) * 2007-04-26 2010-08-26 Rami Skaliter Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system
WO2009055445A2 (en) * 2007-10-22 2009-04-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2229459B1 (en) * 2007-12-13 2014-08-27 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
WO2010011895A1 (en) * 2008-07-25 2010-01-28 Alnylam Pharmaceuticals, Inc. Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand
WO2010048590A1 (en) * 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules
AU2011225748A1 (en) 2010-03-08 2012-09-13 Novartis Ag Methods of testing for intracellular pathogens
AU2012223366B2 (en) * 2011-03-03 2017-02-23 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
EP2694670B1 (en) 2011-04-08 2017-07-19 Bio-Rad Laboratories, Inc. Pcr reaction mixtures with decreased non-specific activity
US11163898B2 (en) * 2013-09-11 2021-11-02 Mimecast Services Ltd. Sharing artifacts in permission-protected archives
WO2016037163A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
CA2962100C (en) 2014-09-26 2020-06-09 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Virus-based expression vectors and uses thereof
WO2019075360A1 (en) 2017-10-13 2019-04-18 Selecta Biosciences, Inc. METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES
US20200390718A1 (en) 2019-05-28 2020-12-17 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
KR20230022150A (ko) * 2020-03-13 2023-02-14 누오-베타 파마슈티컬 테크놀로지 (상하이) 씨오., 엘티디. Pi4k 억제제의 항-코로나바이러스 효과 및 적용
EP4162050A1 (en) * 2020-06-09 2023-04-12 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
EP4527927A1 (en) * 2023-09-22 2025-03-26 Medizinische Hochschule Hannover Oligonucleotide-based strategies to combat respiratory viruses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5693532A (en) 1994-11-04 1997-12-02 Ribozyme Pharmaceuticals, Inc. Respiratory syncytial virus ribozymes
WO1997014792A2 (en) * 1995-10-17 1997-04-24 Hybridon, Inc. Oligonucleotides with anti-respiratory syncytial virus activity
US6214805B1 (en) * 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
RU2322500C2 (ru) * 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
EP1390472A4 (en) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS
WO2003008628A2 (en) 2001-07-20 2003-01-30 Ribozyme Pharmacuticals, Inc. Enzymatic nucleic acid peptide conjugates
US20030203356A1 (en) * 2002-01-22 2003-10-30 The Cleveland Clinic Foundation RNase L activator-antisense complexes
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
US20040204420A1 (en) * 2002-08-05 2004-10-14 Rana Tariq M. Compounds for modulating RNA interference
AU2003279004B2 (en) * 2002-09-28 2009-10-08 Massachusetts Institute Of Technology Influenza therapeutic
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
KR20120038546A (ko) * 2002-11-01 2012-04-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법
MXPA05007651A (es) * 2003-01-16 2005-10-26 Univ Pennsylvania Composiciones y metodos para la inhibicion por arnsi de la molecula de adhesion intercelular-1.
WO2004064737A2 (en) 2003-01-17 2004-08-05 Alnylam Pharmaceuticals Therapeutics compositions
EP3450559A1 (en) 2003-03-07 2019-03-06 Alnylam Pharmaceuticals, Inc. Therapeutic compositions
CA2522349A1 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals, Inc. Protected monomers
ES2702942T3 (es) * 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
EP1689414A4 (en) * 2003-12-04 2009-04-08 Univ South Florida Res Foundat POLYNUCLEOTIDES FOR REDUCING GENE EXPRESSION OF THE RESPIRATORY SYNCYTIAL VIRUS
US7297786B2 (en) 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
JP5081630B2 (ja) * 2005-01-07 2012-11-28 アルナイラム ファーマシューティカルズ， インコーポレイテッド ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法

Similar Documents

Publication Publication Date Title
JP2008517940A5 (enExample)
IL217332A (en) Preparations containing irna materials, pharmaceutical compositions containing them and their use in the manufacture of drugs to lower the level of respiratory virus protein @ syncial @ rsv @@@ mrna @ of @ rsv @ or @ concentration @ of @ rsv
US8309531B2 (en) Administration of interferon for prophylaxis against or treatment of pathogenic infection
Safari et al. CRISPR systems: Novel approaches for detection and combating COVID-19
JP2008526876A5 (enExample)
CN101087527B (zh) RSV、PIV和其它呼吸道病毒的RNAi调节及其用途
WO2011126808A3 (en) Pharmacologically induced transgene ablation system
JP2010500360A (ja) 炎症性サイトカイン阻害剤による下気道炎症疾患の局所療法
JP2010503396A5 (enExample)
EA201000085A1 (ru) dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ
JP2012176990A5 (enExample)
Allen et al. Potential use of RNA-dependent RNA polymerase (RdRp) inhibitors against SARS-CoV2 infection
Du et al. Kaempferide enhances type I interferon signaling as a novel broad-spectrum antiviral agent
Lê et al. Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice
ES3018013T3 (en) Ifn-lambda mrna for treating viral infections
JP2008503569A5 (enExample)
Zhou et al. Complex pathophysiological mechanisms and the propose of the three-dimensional schedule for future COVID-19 treatment
Fonseca et al. Single-cell RNA Sequencing Analysis Identifies Long-term Alterations in Lung Epithelial Cell Distribution and Phenotype After EL-RSV Infection
RU2007115097A (ru) Модуляция rsv, piv и других респираторных вирусов с помощью rnai и ее применение
JP2012020953A5 (enExample)
BR122025002828A2 (pt) Composição, molécula de dna, molécula de mrna, métodos para produzir uma composição e um mrna, e, usos de uma composição e de uma molécula de mrna
Halfhide et al. Chemokine Receptor Expression in Human Respiratory Syncytial Virus (RSV) Bronchiolitis.
Moesker et al. Overview of Human Upper and Lower Respiratory Tract Viral Infections
TH81350A (th) สารผสมสำหรับการให้ทางเยื่อบุเมือก และวิธีของเพิ่มการดูดซึมผ่านเยื่อบุเมือก